A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells  by Quayle, Steven N. & Sadar, Marianne D.
6) 633–637
www.elsevier.com/locate/ygenoGenomics 87 (200A truncated isoform of TMEFF2 encodes a secreted protein in
prostate cancer cells
Steven N. Quayle, Marianne D. Sadar ⁎
Genome Sciences Centre, British Columbia Cancer Agency, and Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada V5Z 4E6
Received 15 September 2005; accepted 11 December 2005
Available online 24 January 2006Abstract
The transmembrane protein TMEFF2, also known as tomoregulin or TENB2, has been proposed as a potential immunotherapeutic target for
the treatment of prostate cancer. Much attention has focused on its limited tissue distribution, with strong expression seen only in the brain and
the prostate. Here we describe the identification of a novel splice variant of TMEFF2 expressed both in the normal prostate and in prostate
cancer. This variant encodes an isoform of TMEFF2 that is truncated after the first four coding exons, eliminating both the EGF-like and the
transmembrane domains. Fusion of GFP to this isoform demonstrated that this variant transcript produces a truncated TMEFF2 protein
(TMEFF2-S). In contrast to full-length TMEFF2–GFP, the truncated TMEFF2-S–GFP fusion protein was enriched in cytosolic granules,
showed no staining at the plasma membrane, and was secreted into the medium of transfected cells grown in tissue culture. These results
indicate that a truncated isoform of TMEFF2 is expressed from this locus. This secreted form of TMEFF2 may functionally interact with full-
length TMEFF2, or its binding partners, and may also influence current immune-based treatment strategies.
© 2005 Elsevier Inc. All rights reserved.Keywords: Prostate cancer; Alternate splicing; Secreted protein; TMEFF2 protein; HumanThe human TMEFF2 (transmembrane protein with EGF-like
and two follistatin-like domains 2) gene was initially described
by a number of independent groups [1–6]. Together, these
reports described TMEFF2 as a proteoglycan predominately
expressed in the brain and prostate. TMEFF2 was also shown to
be hypermethylated in bladder and colorectal tumor cells. While
its full name illustrates its predicted domains, a physiological
role for TMEFF2 has not been determined. Overexpression of
full-length TMEFF2 inhibited the proliferation of two aggres-
sive prostate cancer cell lines [6], while the soluble extracellular
domain of TMEFF2 increased survival of neuronal cells in
primary cultures [3]. Additionally, the TMEFF2 extracellular
domain elicited weak tyrosine phosphorylation of erbB-4 [1].
TMEFF2 has received recent attention as a possible immuno-
therapeutic target for the treatment of metastatic prostate cancer
[7,8]. This interest is due to its restricted expression profile as
well as its increased expression in androgen-independent⁎ Corresponding author. Fax: +1 604 675 8178.
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doi:10.1016/j.ygeno.2005.12.004prostate cancer [5,9]. We report here the identification of a
novel splice variant of TMEFF2 that encodes a secreted protein
(TMEFF2-S).
Results
A novel splice variant is transcribed from the TMEFF2 locus
Previous experiments in our laboratory have generated a
collection of novel expressed sequence tags (EST; unpublished
data) derived from a LNCaP xenograft model of prostate cancer
[10]. Sequencing of one such EST (referred to as EST 2A06)
revealed a 330-bp sequence with 99.1% homology to a region
of chromosome 2q32.3. Upon further analysis, EST 2A06 was
mapped to the fourth intron of the gene TMEFF2 (also known
as tomoregulin-2, HPP1, or TENB2; Fig. 1a). Reverse
transcriptase (RT)-PCR with primers anchored in the known
transcript and EST 2A06 amplified an unidentified product of
approximately 3.3 kb, indicating that EST 2A06 represented a
novel splice variant of the TMEFF2 gene (Fig. 1b). However,
Fig. 1. A novel EST is part of a larger transcript derived from the TMEFF2 locus.
(a) Schematic cartoon summarizing the TMEFF2 genomic locus (transcribed
from left to right) and the relative location of the sequenced EST 2A06 in the
fourth intron (not to scale). Horizontal lines represent introns, vertical lines
represent exons, and filled boxes represent untranslated regions. Numbered
arrows represent the locations of the primers used in (b). (b) Results of RT-
PCR experiment using the primer pairs from (a) indicated above each lane.
These results suggest that EST 2A06 and TMEFF2 share a single transcript.
(c) Schematic cartoon showing the domain structure of the peptide predicted
from the sequence of the novel splice variant. SS, signal sequence; FS,
follistatin-like domain; EGF, EGF-like domain; TM, transmembrane domain;
N, novel amino acid residues.
Fig. 2. The novel splice variant of TMEFF2 is expressed in normal tissues and
produces a truncated protein. (a) RT-PCR was performed with primers located
within EST 2A06 using cDNA from LNCaP, PrEC, and PC3 cell lines, from
normal human cDNAs, and from three samples of prostate cancer (T1, T2, T3)
and their respective matched normal samples (N1, N2, N3). RT-PCR for
GAPDH confirmed the presence and quality of cDNA in each sample. The novel
TMEFF2 transcript was expressed specifically in prostate-derived tissues. (b)
Immunoblot demonstrating expression of the GFP fusion protein constructs.
Whole-cell lysates from LNCaP cells not transfected or transfected with pRc-
CMV, TMEFF2-GFP, or TMEFF2-S-GFP plasmids were immunoblotted using
an anti-GFP antibody. Probing for β-actin confirmed the amount and quality of
protein in each lane. Expression of TMEFF2-S produced a single 50-kDa
protein. All images are representative of multiple experiments.
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TMEFF2 transcript. Sequencing of the 3.3 kb band revealed a
cDNA encoding the first four exons of TMEFF2 followed by
2.9 kb of the fourth intron (GenBank Accession No.
DQ133599). A predicted translation of this cDNA suggested
it encoded a 175-amino-acid open reading frame consisting of
the first 146 residues of TMEFF2 followed by 29, mostly
hydrophobic, residues not found in the normal TMEFF2 protein
sequence. These 29 novel amino acids (GRSCLFTYLKIYW-
WILLCIFTYVCSISDI) did not exhibit significant similarity to
any proteins in GenBank. Significantly, this predicted isoform,
designated TMEFF2-S, lacked one follistatin-like domain, the
EGF-like domain, and the transmembrane domain (Fig. 1c).
TMEFF2-S was expressed in normal human tissues and
produced a truncated protein
To determine the tissue distribution of TMEFF2-S, we
performed RT-PCR with cDNA samples obtained from the
prostatic cell lines LNCaP, PrEC, and PC3; from normal human
tissues; and from samples of prostate cancer and their matched
normal samples (Fig. 2a). While the prostate cancer specimens
were not microdissected, they did contain 65–80% tumor tissue.Additionally, tumor sample T3 expressed the TMEFF2-S
transcript while the matched normal sample N3 showed little
to no expression of this transcript, suggesting that in this case
TMEFF2-S was expressed only by the cancer cells (Fig. 2a). No
bands were detected in the RT-negative samples, indicating this
635S.N. Quayle, M.D. Sadar / Genomics 87 (2006) 633–637product was not due to contamination with genomic DNA.
Identical results were obtained from PCR with two other primer
pairs located in different regions of the TMEFF2-S transcript
(data not shown). Expression of this isoform was limited to
LNCaP cells, normal prostate, and testis. Importantly, TMEFF2-
S expression was also observed in prostate cancer specimens.
To demonstrate that this splice variant produced a truncated
protein as predicted from its cDNA sequence, GFP was fused to
the carboxyl terminus of both full-length TMEFF2 and
TMEFF2-S. Each isoform was transfected into LNCaP cells
and expression of the fusion proteins monitored by Western blot
analysis of whole-cell protein lysates using an anti-GFP
antibody. As predicted, the full-length TMEFF2–GFP fusion
protein was approximately 75 kDa (Fig. 2b); there were,
however, other products of this fusion protein, most likely due
to posttranslational modifications. The extracellular domain of
TMEFF2 was previously shown to be cleaved at multiple sites,
leaving small portions of the full-length protein in the plasma
membrane [1,5]. This protein is also known to be glycosylated,
thus altering its predicted migration pattern in acrylamide gels
[1,5]. In contrast, the TMEFF2-S–GFP fusion protein produced
a single molecular weight species of approximately 50 kDa,
close to the predicted size of 48 kDa. A doublet band of aboutFig. 3. The truncated variant of TMEFF2 is not localized in the plasma membran
subcellular localization of GFP fusion proteins. LNCaP cells transfected with either T
and counterstained with DAPI prior to visualization by fluorescence microscopy. Th
shows the overlay of these images. TMEFF2-S–GFP was not present in the plasma m
All images were captured at 630× magnification. (b) Immunoblot demonstrating the p
LNCaP cells were not transfected or were transfected with pRc-CMV, TMEFF2–GF27 kDa probably represents free GFP produced from internal
ribosome entry into the fusion transcripts, as this band was
present regardless of the fusion protein being expressed. An
unexpected band of 21 kDa was also seen. The identity of this
band is unclear, but probably represents a cleavage product of
the GFP protein, as the antibody used was raised against the
full-length GFP sequence. These results confirm that the
TMEFF2-S transcript identified does encode a truncated
protein.
The truncated isoform of TMEFF2 produced a secreted protein
The predicted protein sequence of TMEFF2-S lacks a
transmembrane domain (Fig. 1c); this may alter its subcellular
localization compared with full-length TMEFF2. To determine
this, LNCaP cells transfected with the GFP fusion proteins were
examined by fluorescence microscopy (Fig. 3a). As predicted,
cells transfected with TMEFF2–GFP showed diffuse cytoplas-
mic localization with strong signal in the plasma membrane
(Fig. 3a, top). In contrast, cells expressing the TMEFF2-S–GFP
splice variant showed no signal in the plasma membrane (Fig.
3a, bottom). All TMEFF2-S–GFP fluorescence was observed in
bright foci in the cytoplasm, again in contrast with the diffusee but is secreted by transfected cells. (a) Fluorescence micrographs showing
MEFF2-GFP (top row) or TMEFF2-S-GFP (bottom row) constructs were fixed
e left shows GFP signal, the middle shows DAPI-stained nuclei, and the right
embrane, but instead all GFP signal was present in discrete foci in the cytoplasm.
resence of the TMEFF2-S–GFP fusion protein in the media of transfected cells.
P, or TMEFF2-S–GFP. All images are representative of multiple experiments.
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subcellular localization of TMEFF2-S was distinct from that of
TMEFF2.
Given that the truncated TMEFF2 protein still contained the
putative signal sequence while lacking the transmembrane
region, we proposed to determine whether the truncated
TMEFF2 protein was secreted. Western blot analysis using
anti-GFP antibody detected a distinct band of approximately 50
kDa only in the medium of cells expressing the TMEFF2-S–
GFP protein (Fig. 3b). The intensity of this band increased with
increasing amounts of plasmid DNA transfected (Fig. 3b). The
TMEFF2-S–GFP protein detected in the medium migrated the
same distance as TMEFF2-S–GFP in whole-cell lysates (data
not shown). No GFP-reactive proteins were seen in the medium
of cells expressing full-length TMEFF2 or in culture medium.
The secretion of TMEFF2-S suggests this isoform may have a
function distinct from that of TMEFF2.
Discussion
The expression of splice variants from a single genomic locus
allows for greater diversity of gene products without the need for
enlarging the entire genome. Alternative splicing events have
been associated with a number of genetic diseases, including
cancer [11]. Often, these splice variants alter the function of the
other gene products expressed from that locus [12,13]. There are
multiple examples of transmembrane proteins with splice
variants lacking the transmembrane domain, resulting in a
secreted isoform of the protein [13,14]. This is the first report to
describe a secreted isoform of TMEFF2.
Full-length TMEFF2 is expressed predominately in the brain
and in the prostate, with even stronger expression seen in
prostate cancer [3,5,7]. In agreement with these data, expression
of TMEFF2-S was detected in LNCaP prostate cancer cells, in
normal and cancerous human prostate tissue, and weakly in
human testis tissue. Previous studies have detected an
unidentified minor band of approximately 3.5 kb when probing
for TMEFF2 by Northern blot analysis [3,5,6]. The probes used
in those experiments would overlap with the novel splice variant
described here, and thus the 3.5-kb band observed may represent
this truncated form of TMEFF2. Full-length TMEFF2 expres-
sion appears to be androgen-regulated and also repressed by the
c-Myc protein [5,6,15], but whether the truncated isoform is also
regulated in this manner is not yet known. It will be of interest to
assess whether the expression level of TMEFF2-S changes with
the progression of prostate cancer, as this is seen for full-length
TMEFF2 [6]. Intriguingly, the expression of the minor 3.5-kb
band decreased after castration in the CWR22 model, but the
kinetics of this decrease appeared different from that of full-
length TMEFF2 [6]. The expression patterns of these isoforms in
both normal and cancerous tissues need to be assessed to help
elucidate their potential roles in carcinogenesis.
The precise function(s) of TMEFF2 needs to be examined
further, as does the relationship of these isoforms. It will be
interesting to determine if TMEFF2-S functionally interacts
with TMEFF2 through cooperative signaling events or
competitive binding. A thorough examination of the differentbinding partners of the various forms of TMEFF2 may help in
this regard. Expression of full-length TMEFF2 in the prostate is
restricted to the luminal epithelial cells [7,8]. Given the
similarities in their expression profiles it is likely both proteins
are expressed in this cell type, suggesting these isoforms may
have roles in the normal secretory functions of the prostate. The
extracellular domain of TMEFF2 can be cleaved, resulting in at
least two different soluble proteins [1,5]. This cleaved form of
TMEFF2 may be responsible for its functional effects and the
soluble TMEFF2-S protein may then negatively regulate, or
synergize with, cleaved TMEFF2. One form of cleaved
TMEFF2 produces a soluble protein with both follistatin-like
(FS) domains intact, but without the EGF-like domain,
suggesting these FS domains act in concert. In contrast,
TMEFF2-S contains only one FS domain. The absence of one
FS domain may then enhance, or inhibit, the activity of this
secreted isoform relative to the cleaved TMEFF2 peptide.
Additionally, the loss of the EGF-like domain implies
TMEFF2-S would not induce phosphorylation of erbB4, in
contrast to TMEFF2 [1]. The delineation of the functions of
these isoforms will be made simpler once a reliable screen for
TMEFF2 activity has been established.
Recently, two groups have published reports proposing the
use of antibodies directed against TMEFF2 in the treatment of
prostate cancer [7,8]. While both studies reported favorable
results, the presence of a soluble form of TMEFF2 may not have
been considered when these antibodies were designed. Clearly,
further studies will be required to examine the circulating levels
of TMEFF2-S in these patients and whether the secreted isoform
may cross-react with the antibodies used. If so, the TMEFF2-S
protein may decrease the efficacy of this approach by compe-
titively binding the antibody away from the tumor cells.
Alternatively, targetingofTMEFF2-Smayprovide added benefit
to patients by altering the normal function of this novel isoform.Materials and methods
Cell culture and transfection
LNCaP cells obtained from Dr. L.W.K. Chung (Emory University School of
Medicine, Atlanta, GA,USA)weremaintained inRPMI 1640 supplementedwith
5% (v/v) fetal bovine serum (FBS) (HyClone, Logan, UT, USA), 100 units/ml
penicillin, and 100 μg/μl streptomycin (Invitrogen, Burlington, ON, Canada).
All chemicals were purchased from Sigma, unless stated otherwise. Androgen
stimulation was performed by treatment with the synthetic androgen R1881
(10 nM; Perkin–Elmer, Woodbridge, Canada) for 24 h. For transfections,
LNCaP cells were plated at 3.0 × 105 cells per well in six-well plates. After 24 h,
transfections were performed using Lipofectin reagent (Invitrogen) according to
the manufacturer’s protocol. Plasmids encoding full-length or truncated
TMEFF2 were transfected at 1 and 3 μg/well in separate wells. The total
amount of transfected DNAwas normalized to 3 μg/well by the addition of pRc-
CMV (Invitrogen) plasmid encoding the CMV promoter but lacking a
downstream gene. After 24 h RPMI 1640 was added to the cells to a final
concentration of 5% FBS.
RT-PCR
Total RNA was isolated from LNCaP cells maintained in vivo [10] or in
vitro, PrEC cells (Clonetics, Guelph, Canada), or PC3 prostate cancer cells using
Trizol reagent (Invitrogen) according to the manufacturer’s protocol. Total RNA
637S.N. Quayle, M.D. Sadar / Genomics 87 (2006) 633–637samples from several normal human tissues were purchased from Stratagene (La
Jolla, CA, USA). Samples of total RNA from cases of prostate cancer, and their
matched normal samples, were purchased from Genomics Collaborative
(Cambridge, MA, USA). Reverse transcription was performed using MMLV-
RT (Invitrogen) with 1 μg of template RNA. Subsequent PCRs were performed
using 1 μl of the resulting cDNA as template. Primers used to amplify TMEFF2
and EST 2A06were as follows: primer 1, 5′-CCCGTCATGCTACTCATCGT-3′;
primer 2, 5′-CTGAACAAAAGAGTGAAGGGAAC-3′; primer 3, 5′-CCCTT-
GTGCAAATGGGTTA-3′; and primer 4, 5′-AATGCTCACACTTCCCATGC-
3′. The primers used to detect GAPDH were forward, 5′-CCGAGCCACA-
TCGCTCAGA-3′, and reverse, 5′-CCCAGCCTTCTCCATGGTG-3′.
Plasmids
A Mammalian Gene Collection expression clone (Clone ID 4180709)
containing the entire transcript for TMEFF2 was purchased from Invitrogen.
The open reading frames of full-length and truncated TMEFF2 were cloned into
pcDNA3.1D/V5-His-TOPO vector (Invitrogen) using the forward primer 5′-
CACCATGGTGCTGTGGGAGTCC-3′, TMEFF2-reverse 5′-GATTAACCTC-
GTGGACGCTC-3′, and truncated TMEFF2-reverse 5′-AATATCTGAAATG-
GAACATAC-3′. The same forward primer was used to amplify both open
reading frames. These inserts were then removed by digesting with HindIII and
EcoRV restriction endonucleases, followed by ligation into theHindIII and SmaI
sites of the pEGFP-N3 vector. All plasmids were sequence verified.
Western blot analysis
LNCaP cells were harvested and washed twice in ice-cold PBS. Cell pellets
were lysed in 2× SDS–PAGE loading buffer and boiled for 5 min prior to being
loaded on 12% SDS–PAGE gels. Medium from transfected cells was removed
after incubation for 24 h and centrifuged to remove unattached cells, and 25 μl
samples were analyzed on 12% SDS–PAGE gels. The separated proteins were
transferred to nitrocellulose membranes (Amersham Biosciences, Piscataway,
NJ, USA) and blocked in Odyssey blocking buffer (LI-COR Biosciences,
Lincoln, NE, USA) for 1 h at room temperature or at 4°C overnight and then
washed three times. The blots were probed with anti-GFP (B-2) (1:500) (Santa
Cruz Biotechnology) or anti-β-actin (ab6276) (1:5000) (Abcam, Cambridge,
MA, USA) for 1 to 2 h at room temperature, washed three times, and incubated
with the appropriate IR-labeled secondary antibody (1:5000; Molecular Probes)
for 30 min at room temperature. All washes were performed with PBS
containing 0.1% Tween 20. Primary antibodies were diluted in Odyssey
blocking buffer with 0.1% Tween 20, while secondary antibody dilutions
contained an additional 0.01% SDS. Visualization was performed with the
Odyssey infrared imaging system (LI-COR Biosciences).
Fluorescence microscopy
LNCaP cells (3.0 × 105 cells per well) were plated on sterile coverslips in
six-well plates. Transfections were performed as described above. The cells
were fixed for 30 min in 4% paraformaldehyde at room temperature, followed
by two washes in sterile PBS. Nuclei were counterstained with 300 nM 4′,6-
diamidino-2-phenylindole (DAPI) for 5 min at room temperature. The cells were
again rinsed in sterile PBS prior to being mounted on glass slides. Images were
captured using an AxioCam high-resolution color camera on an AxioPlan 2
fluorescence microscope (Carl Zeiss, Toronto, ON, Canada). Images of the GFP
and DAPI channels were merged using Adobe PhotoShop software.Acknowledgments
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